A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder

Journal of Clinical Psychiatry

Volumn 73, Issue 12, 2012, Pages 1517-1523

  Manor, Iris ^a,b   Ben Hayun, Rachel ^c   Aharon Peretz, Judith ^c   Salomy, Dana ^a   Weizman, Abraham ^a,b   Daniely, Yaron ^d   Megiddo, Dalia ^d   Newcorn, Jeffrey H ^e   Biederman, Joseph ^g   Adler, Lenard A ^f  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Rambam Health Care Campus ^*  (Israel)

^d Alcobra Ltd   (Israel)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METADOXINE; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BACKACHE; CONCENTRATION LOSS; CONNERS ADULT ADHD RATING SCALE INVESTIGATOR RATED; CONTROLLED STUDY; DECREASED APPETITE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; NAUSEA; OROPHARYNX PAIN; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STOMACH PAIN; TEST OF VARIABLES OF ATTENTION; UPPER ABDOMINAL PAIN;

EID: 84871846030     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m07767     Document Type: Article

References (35)

1. Biederman J, Petty CR, Clarke A, et al. Predictors of persistent ADHD: an 11-year follow-up study. J Psychiatr Res. 2011;45(2):150-155. doi:10.1016/j.jpsychires.2010.06.09 PubMed
2. Biederman J, Petty CR, Evans M, et al. How persistent is ADHD? a controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299-304. doi:10.1016/j.psychres.209.12.010 PubMed
3. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the National Comorbidity Survey Replication. Biol Psychiatry. 2005;57(11):1442-1451. doi:10.1016/j.biopsych.205.04.01 PubMed (Pubitemid 40798566)
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723. PubMed (Pubitemid 44464584)
5. Rösler M, Retz W, Retz-Junginger P, et al. Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci. 2004;254(6):365-371. doi:10.107/s0406-04-0516-z PubMed (Pubitemid 40192991)
6. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524-540. doi:10.408/JCP.v67n0403 PubMed (Pubitemid 43764229)
7. Reimer B, Mehler B, D'Ambrosio LA, et al. The impact of distractions on young adult drivers with attention deficit hyperactivity disorder (ADHD). Accid Anal Prev. 2010;42(3):842-851. doi:10.1016/j.ap.209.06.021 PubMed
8. Biederman J, Arnsten AF, Faraone SV, et al. New developments in the treatment of ADHD. J Clin Psychiatry. 2006;67(1):148-159. doi:10.408/JCP. v67n0121 PubMed
9. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21-31. doi:10.1097/chi.0b013e31815a56f1 PubMed
10. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754-763. doi:10.408/JCP.08m04902pur PubMed
11. Vitamin B6 (pyridoxine and pyridoxal 5′-phosphate). Altern Med Rev. 2001;6(1):87-92. PubMed
12. Díaz Martínez MC, Díaz Martínez A, Villamil Salcedo V, et al. Efficacy of metadoxine in the management of acute alcohol intoxication. J Int Med Res. 2002;30(1):44-51. PubMed (Pubitemid 34618721)
13. Fornai F, Grazia Alessandrì M, Bonuccelli U, et al. Effect of metadoxine on striatal dopamine levels in C57 black mice. J Pharm Pharmacol. 1993;45(5):476-478. doi:10.1/j.2042-7158.193.tb0579.x PubMed (Pubitemid 23162450)
14. Guilarte TR, Wagner HN Jr, Frost JJ. Effects of perinatal vitamin B6 deficiency on dopaminergic neurochemistry. J Neurochem. 1987;48(2):432-439. doi:10.1/j.1471-4159.1987.tb041.x PubMed (Pubitemid 17005150)
15. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201. doi:10.1016/j.psc.203.12.03 PubMed (Pubitemid 38452762)
16. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (SCID-I/P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 2002.
17. Guy W. Clinical global impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology (revised). US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:217-221.
18. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-571. doi:10.101/archpsyc.1961. 017101203104 PubMed
19. Spielberger CD. State-Trait Anxiety Inventory (STAI: Form Y). Palo Alto, CA: Consulting Psychologists Press; 1983.
20. Greenberg LM, Waldman ID. Developmental normative data on the Test of Variables of Attention (TOVA). J Child Psychol Psychiatry. 1993;34(6):1019-1030. PubMed (Pubitemid 23266106)
21. Brod M, Johnston J, Able S, et al. Validation of the Adult Attention-Deficit/Hyperactivity Disorder Quality-of-Life Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006;15(1):117-129. doi:10.107/s136-05-8325-z PubMed (Pubitemid 43097592)
22. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales. North Tonawanda, NY: Multi-Health Systems, Inc; 1999.
23. Van Voorhees EE, Hardy KK, Kollins SH. Reliability and validity of self- and other-ratings of symptoms of ADHD in adults. J Atten Disord. 2011;15(3):224-234. doi:10.17/1087054709356163 PubMed
24. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. doi:10.176/api.ajp.201.101704 PubMed
25. Adler LA, Spencer T, Faraone SV, et al. Training raters to assess adult ADHD: reliability of ratings. J Atten Disord. 2005;8(3):121-126. doi:10.17/108705470527168 PubMed (Pubitemid 40805795)
26. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
27. Durell T, Adler L, Wilens T, et al. Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord. 2010;13(4):401-406. doi:10.17/108705470934203 PubMed
28. Goodman D, Faraone SV, Adler LA, et al. Interpreting ADHD Rating Scale scores: linking ADHD Rating Scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Prim Psychiatry. 2010;17(3):44-52.
29. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44-50. doi:10.1097/JCP.0b013e318192e4a0 PubMed
30. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456-463. doi:10.1016/j.biopsych.204.1.043 PubMed (Pubitemid 40311979)
31. Weiss MD, Gibbins C, Goodman DW, et al. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(4):381-390. Published online Feb 23, 2010. doi:10.408/JCP.08m04709pur PubMed
32. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005;66(2):253-259. doi:10.408/JCP.v6n0215 PubMed (Pubitemid 40314334)
33. Hammerness PG, Surman CB, Chilton A. Adult attention-deficit/ hyperactivity disorder treatment and cardiovascular implications. Curr Psychiatry Rep. 2011;13(5):357-363. doi:10.107/s1920-01-0213-3 PubMed
34. Cohen M, Bendich A. Safety of pyridoxine: a review of human and animal studies. Toxicol Lett. 1986;34(2-3):129-139. doi:10.1016/0378-4274(86)90202-X PubMed (Pubitemid 17223707)
35. Addolorato G, Ancona C, Capristo E, et al. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int J Immunopathol Pharmacol. 2003;16(3):207-214. PubMed (Pubitemid 39011225)